Clinical trial
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV…
NCT00148941 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00148941 |
|---|---|
| Title | Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines |
| Official title | Safety, Immunogenicity and Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine Versus Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Administered as Booster Doses to Healthy Children 4-6 Years, Each Co-administered With Merck's MMR Vaccine |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tetanus, Acellular Pertussis, Diphtheria |
| Intervention type | Biological |
| Interventions | SB213503 lot 1, SB213503 lot 2, SB213503 lot 3, Infanrix, IPOL, M-M-R II |
| Enrollment | 4,209 |
| Start date | Jan 6, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Dec 4, 2006 |
| First posted | Sep 8, 2005 |
| Last update posted | Feb 5, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: